WO2006085321A3 - Compositions and methods for purifying and crystallizing molecules of interest - Google Patents

Compositions and methods for purifying and crystallizing molecules of interest Download PDF

Info

Publication number
WO2006085321A3
WO2006085321A3 PCT/IL2006/000173 IL2006000173W WO2006085321A3 WO 2006085321 A3 WO2006085321 A3 WO 2006085321A3 IL 2006000173 W IL2006000173 W IL 2006000173W WO 2006085321 A3 WO2006085321 A3 WO 2006085321A3
Authority
WO
WIPO (PCT)
Prior art keywords
interest
purifying
compositions
methods
composition
Prior art date
Application number
PCT/IL2006/000173
Other languages
French (fr)
Other versions
WO2006085321A2 (en
Inventor
Guy Patchornik
Original Assignee
Affisink Biotechnology Ltd
Guy Patchornik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16680005A external-priority patent/IL166800A0/en
Priority claimed from US11/330,112 external-priority patent/US20060121519A1/en
Application filed by Affisink Biotechnology Ltd, Guy Patchornik filed Critical Affisink Biotechnology Ltd
Priority to CA002597136A priority Critical patent/CA2597136A1/en
Priority to EP06711155A priority patent/EP1856528A2/en
Publication of WO2006085321A2 publication Critical patent/WO2006085321A2/en
Publication of WO2006085321A3 publication Critical patent/WO2006085321A3/en
Priority to US11/826,906 priority patent/US7956165B2/en
Priority to IL184741A priority patent/IL184741A0/en
Priority to US13/083,634 priority patent/US20110256525A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A composition of matter is provided. The composition comprising at least one antibody binding moiety capable of binding an antibody-labeled target molecule, cell or virus of interest, said at least one antibody binding moiety being attached to at least one coordinating moiety selected capable of directing the composition of matter to form a non-covalent complex when co-incubated with a coordinator ion or molecule.
PCT/IL2006/000173 2003-07-24 2006-02-09 Compositions and methods for purifying and crystallizing molecules of interest WO2006085321A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002597136A CA2597136A1 (en) 2005-02-10 2006-02-09 Compositions and methods for purifying and crystallizing molecules of interest
EP06711155A EP1856528A2 (en) 2005-02-10 2006-02-09 Compositions and methods for purifying and crystallizing molecules of interest
US11/826,906 US7956165B2 (en) 2003-07-24 2007-07-19 Compositions and methods for purifying and crystallizing molecules of interest
IL184741A IL184741A0 (en) 2005-02-10 2007-07-19 Compositions and methods for purifying and crystallizing molecules of interest
US13/083,634 US20110256525A1 (en) 2003-07-24 2011-04-11 Compositions and methods for purifying and crystallizing molecules of interest

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL166800 2005-02-10
IL16680005A IL166800A0 (en) 2005-02-10 2005-02-10 Compositions for separating and crystallizing of molecules
US11/330,112 US20060121519A1 (en) 2003-07-24 2006-01-12 Compositions and methods for purifying and crystallizing molecules of interest
US11/330,112 2006-01-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/330,112 Continuation-In-Part US20060121519A1 (en) 2003-07-24 2006-01-12 Compositions and methods for purifying and crystallizing molecules of interest

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2007203370A Division AU2007203370A1 (en) 2005-02-10 2007-07-19 Compositions and Methods for Purifying and Crystallizing Molecules of Interest
US11/826,906 Continuation-In-Part US7956165B2 (en) 2003-07-24 2007-07-19 Compositions and methods for purifying and crystallizing molecules of interest

Publications (2)

Publication Number Publication Date
WO2006085321A2 WO2006085321A2 (en) 2006-08-17
WO2006085321A3 true WO2006085321A3 (en) 2007-04-12

Family

ID=36218193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000173 WO2006085321A2 (en) 2003-07-24 2006-02-09 Compositions and methods for purifying and crystallizing molecules of interest

Country Status (3)

Country Link
EP (1) EP1856528A2 (en)
CA (1) CA2597136A1 (en)
WO (1) WO2006085321A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
DK2370561T3 (en) 2008-12-16 2019-10-21 Emd Millipore Corp Stirring tank reactor and process
EP3597671B1 (en) 2010-05-17 2022-09-21 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US10030224B2 (en) 2015-11-01 2018-07-24 Ariel-University Research And Development Company Ltd. Methods of analyzing cell membranes
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010141A2 (en) * 2003-07-24 2005-02-03 Affisink Biotechnology Ltd. Compositions for purifying and crystallizing molecules of interest

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010141A2 (en) * 2003-07-24 2005-02-03 Affisink Biotechnology Ltd. Compositions for purifying and crystallizing molecules of interest

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARINAGA-REMENTERIA RAMIREZ I ET AL: "Purification of caveolae by affinity two-phase partitioning using biotinylated antibodies and NeutrAvidin-dextran", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 331, no. 1, 1 August 2004 (2004-08-01), pages 17 - 26, XP004520191, ISSN: 0003-2697 *
PATCHORNIK GUY ET AL: "Free nonimmobilized ligands as a tool for purification of proteins", BIOCONJUGATE CHEMISTRY, vol. 16, no. 5, September 2005 (2005-09-01), pages 1310 - 1315, XP002379767, ISSN: 1043-1802 *
ZHONG R K ET AL: "Human blood dendritic cell-like B cells isolated by the 5G9 monoclonal antibody reactive with a novel 220-kDa antigen.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 1999, vol. 163, no. 3, 1 August 1999 (1999-08-01), pages 1354 - 1362, XP002380284, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2006085321A2 (en) 2006-08-17
CA2597136A1 (en) 2006-08-17
EP1856528A2 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
WO2006085321A3 (en) Compositions and methods for purifying and crystallizing molecules of interest
WO2009010976A3 (en) Compositions and methods for purifying and crystallizing molecules of interest
WO2008022295A3 (en) Prlr-specific antibody and uses thereof
WO2008122039A3 (en) Selenocysteine mediated hybrid antibody molecules
WO2005117973A3 (en) Bispecific binding agents for modulating biological activity
WO2006119107A3 (en) Sclerostin binding agents
WO2006119062A3 (en) Sclerostin epitopes
WO2006028936A3 (en) Heteromultimeric molecules
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
WO2007068485A3 (en) Biological materials and uses thereof
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2007089753A3 (en) Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
IL220412A0 (en) Antibodies which bind to gm-csf, polynucleotides encoding the same, pharmaceutical compositions containing the same and uses thereof
WO2007130453A3 (en) Non-natural amino acid substituted polypeptides
IL172938A (en) Anti-glypican 3 antibodies, cell growth inhibitors, pharmaceutical compositions containing the same and uses thereof
WO2006069001A3 (en) Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
WO2013061163A3 (en) Tdp-43 specific binding molecules
WO2008003103A3 (en) Novel multivalent immunoglobulins
NO20060400L (en) Compositions for the Purification and Crystallization of Molecules of Interest
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2007009018A3 (en) Il-6 binding proteins
WO2009043027A3 (en) Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
WO2006129828A3 (en) Target substance capturing molecule
WO2007008072A3 (en) CROSS-ß STRUCTURE BINDING COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 184741

Country of ref document: IL

Ref document number: 11826906

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2597136

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006711155

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006711155

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11826906

Country of ref document: US